Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction.
Adenocarcinoma of the esophagogastric junction (AEG) is a common upper gastrointestinal malignancy.
This study investigates the impact of long non-coding RNA NORAD on the short-term efficacy of oxaliplatin-based neoadjuvant chemotherapy in AEG.
Patients with advanced AEG received oxaliplatin-based neoadjuvant chemotherapy. Oxaliplatin- sensitive (PDCs) and oxaliplatin-resistant (PDC-Rs) primary tumor cell lines were established, and NORAD- knockdown PDC-R cells (shNORAD PDC-R) were generated. NORAD expression in pretreatment tumor tissues was measured by qRT-PCR. The half-maximal inhibitory concentration (IC50) was determined for all cell lines.
NORAD expression correlated with Lauren classification. The low-expression group showed higher overall response rate, tumor regression grade, and pathological remission rate after chemotherapy. Pretreatment NORAD expression was an independent predictor of 3-year disease-free survival (DFS). IC50 values for PDC, PDC-R, and shNORAD PDC-R cells were 2.32, 21.41, and 3.82 μg/mL oxaliplatin, respectively.
High pretreatment NORAD expression is an independent risk factor for poor response to neoadjuvant chemotherapy. Downregulating NORAD restores oxaliplatin sensitivity in resistant cells.
This study investigates the impact of long non-coding RNA NORAD on the short-term efficacy of oxaliplatin-based neoadjuvant chemotherapy in AEG.
Patients with advanced AEG received oxaliplatin-based neoadjuvant chemotherapy. Oxaliplatin- sensitive (PDCs) and oxaliplatin-resistant (PDC-Rs) primary tumor cell lines were established, and NORAD- knockdown PDC-R cells (shNORAD PDC-R) were generated. NORAD expression in pretreatment tumor tissues was measured by qRT-PCR. The half-maximal inhibitory concentration (IC50) was determined for all cell lines.
NORAD expression correlated with Lauren classification. The low-expression group showed higher overall response rate, tumor regression grade, and pathological remission rate after chemotherapy. Pretreatment NORAD expression was an independent predictor of 3-year disease-free survival (DFS). IC50 values for PDC, PDC-R, and shNORAD PDC-R cells were 2.32, 21.41, and 3.82 μg/mL oxaliplatin, respectively.
High pretreatment NORAD expression is an independent risk factor for poor response to neoadjuvant chemotherapy. Downregulating NORAD restores oxaliplatin sensitivity in resistant cells.